OpenAI has acquired Orchestra Bio to integrate its capabilities into the Rosalind life sciences platform for developing pharmaceutical AI agents.

OpenAI has acquired Orchestra Bio, a startup that helps pharmaceutical companies coordinate drug research; the deal size remains undisclosed. Orchestra will be integrated into OpenAI's Rosalind life sciences platform with the goal of building AI agents that connect scientific discovery to clinical trials and decision-making—for example, tracking trials, suggesting affected timelines and offering next steps when production batches fail. OpenAI has already launched AI pharmaceutical research collaborations with Novo Nordisk and Moderna.